Boehringer Ingelheim (Germany)

Boeheringer Ingelheim is a sizeable German pharmaceutical company with a growing presence in the US and other international markets. It has bolstered its US presence through local acquisitions, including Zantac OTC and part of the Fort Dodge Animal Health division. Other key brands include Flomax, Spiriva and Dulcolax. Worldwide sales were E12.7bn in 2009. The group was founded in 1885 by Andreas Boehringer and was run by members of the family until the early 1990s. It is still privately owned. Andreas Barner is executive chairman. Advertising Age/Kantar reported measured expenditure of $247m for 2009, out of an estimated total of $411m. Adbrands does not currently profile this company but subscribers may access account assignments and contact information. The searchable account assignments database is available to full subscribers to Adbrands.net premium services. Click here to access Adbrands account assignments (subscribers only); or see here for information on how to subscribe.

Adbrands Company Profiles assess more than 1,000 leading advertisers, brands and agencies, and examine each company's business record, geographic strength and comparative performance within its chosen sector, including strengths and weaknesses, history, up-to-date news and top-line financial information. What else does the company do? How did it originate? What other brands does it own? How is it performing in the market? With what other businesses is it affiliated?

Adbrands Account Assignments is a database tracking account management for the world's leading brands and companies. In other words, which advertising agency handles which accounts in which countries. Fully searchable by brand, brandowner company or advertising agency, the database now contains more than 15,000 worldwide account assignments for over 4,000 leading brands.

More about Company Profiles | More about Account Assignments

New to the industry? See here for a brief summary of how the agency business is structured.